
Injectable Medication Guideline:
Synagis (Palivizumab)
Background:
Respiratory syncytial virus (RSV) is a common disease of childhood and causes acute upper respiratory tract infections in patients of all ages. Most RSV-infected infants experience upper respiratory tract symptoms, and 20% to 30% develop lower respiratory tract infections with their first RSV infection. Certain conditions increase the risk of severe or fatal RSV infection. These include preterm birth; cyanotic or complicated congenital heart disease, especially when the condition causes pulmonary hypertension; chronic lung disease of prematurity, and immunodeficiency disease or therapy causing immunosuppression at any age. In the U.S., more than 125,000 hospitalizations due to RSV infection occur annually. Outbreaks of RSV usually begin in November or December, peak in January or February, and end in March or April.
Synagis (palivizumab), a humanized mouse RSV monoclonal antibody, has been shown to reduce the risk of serious RSV disease and to reduce RSV-related hospitalizations in high-risk infants and children. Synagis is administered at a dose of 15mg/kg once every 30 days. Five monthly doses will provide more than 20 weeks of protective serum antibody concentration for most infants. Synagis is administered intramuscularly (IM). Synagis is not effective in the treatment of RSV and it is not approved or recommended for this indication. Synagis is FDA-approved for the prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease. Safety and efficacy were established in infants with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (≤ 35 weeks gestation), and children with hemodynamically significant congenital heart disease (CHD). Synagis is associated with high cost. Patients receiving Synagis must meet strict approval criteria.
Criteria (based on documented RSV risk factors):
Infants born at 28 weeks gestation or earlier and who are less than 12 months of age as of November
1st. A maximum of five monthly doses is recommended for patients in this category.
Infants born between 29 to 32 weeks gestation and who are less than 6 months of age as of
November 1st. A maximum of five monthly doses is recommended for patients in this category.
Infants born between 32 to 35 weeks gestation and who are less than 3 months of age as of
November 1st and who have one of the following two risk factors for hospitalization due to RSV:
Infant attends child care, defined as a home or facility where care is provided for any number of
infants or young toddlers in the child care facility; or
Infant has school age siblings or school age relatives living in the house
Infants in this category may receive prophylaxis with Synagis until they reach 3 months of age
and should receive a maximum of 3 monthly doses.
Infants with chronic lung disease (CLD) who are less than 2 years of age as of November 1st who are
receiving or have received medical therapy for CLD within the past 6 months (includes supplemental oxygen, nebulizer treatments, bronchodilators, diuretics, or chronic corticosteroid therapy). A maximum of five monthly doses is recommended for patients in this category.
Infants born before 35 weeks gestation who have congenital abnormalities of the airway or
neuromuscular disease. A maximum of five monthly doses is recommended for patients in this category.
Infants and children who are less than 2 years of age as of November 1st with hemodynamically
significant cyanotic or acyanotic congenital heart disease. Those most likely to benefit are infants and children receiving medication for congestive heart failure (digoxin, diuretic), those with moderate to severe pulmonary hypertension, and those with cyanotic heart disease. A maximum of five monthly doses is recommended for patients in this category.
Infants and children with immune deficiency who may benefit from RSV prophylaxis (severe
combined immunodeficiency, acquired immunodeficiency syndrome (HIV/AIDS), transplant recipients, or children immunocompromised due to chemotherapy). A maximum of five monthly doses is recommended for patients in this category.
呼吸道合胞病毒单克隆抗体的制备及鉴定_专业资料。目的:建立能稳定分泌抗呼吸道合胞病毒(RSV-long株,国际标准株)单克隆抗体的杂交瘤细胞株。方法:杂交瘤技术制备...
人源抗呼吸道合胞病毒基因工程单克隆抗体Fab段基因的筛选和表达_专业资料。...方法从RSV感染患儿恢复期外周血淋巴细胞中提取细胞总RNA,用一组人IgGF出特异性...
单克隆抗体在呼吸道合胞病毒感染诊断和防治中的应用_能源/化工_工程科技_专业资料。今日推荐 160份文档 四级养生 中医养生与保健 中医养生知识大全 女人养生之道...
呼吸道合胞病毒抗原检测试剂盒(胶体金法)说明书_化学_自然科学_专业资料。...单克隆抗体可能不能检测所有抗原变异株或新株 RSV。 预期值 RSV 的流行年年不...
在80年代,随着单克隆抗体的应用,有学者根据合胞病毒分离株同 单克隆抗体的反应性将呼吸道合胞病毒分为A和B两个主要的抗原亚型。 RT-PCR分型检测方法。随着cDNA...
预防的药物有静脉用呼吸道合胞病毒免疫 球蛋白(RsV—IVIG)和抗RsV单克隆抗体。...这两种方法对防止RsV感染都安全有效,但费 用较高,适用于在流行季节高危患儿。 ...
牛呼吸道合胞体病毒核蛋白的表达及其单克隆抗体的制备_马磊_生物学_自然科学...使用上游引物作为反转录引物,按照 Primerscript 的使用说明书进行反转录制备 cDNA...
并发诱导呼吸道合胞病毒(RSV)中和抗体的合成肽疫苗是预防RSV感染的有效途径。本文叙述了用针对RSV F蛋白构象表位的单克隆抗体MAb19筛选固组组合肽库,鉴定出与MAb...
目的建立检测呼吸道合胞病毒(RSV)的快速细胞培养法,并应用于呼吸道合胞病毒感染的早期诊断。方法采用自制的抗RSV的单克隆抗体,经快速细胞培养法和直接涂片法检测165...
目的: 从大容量噬菌体抗体库中筛选人源性抗呼吸道合胞病毒 F蛋白的单链抗体。...aCHP 山羊抗兔单 克隆抗体购自北京中杉金桥公司。 12.方法121.. 噬菌体抗体...
热门文档